Modification of intracellular hemoglobin with pyridoxal and pyridoxal 5'-phosphate. 1982

J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida

The aldehyde forms of vitamin B6, pyridoxal and pyridoxal 5'-phosphate (PLP) have aroused interest as antisickling agents because of their ability to modify hemoglobin (Hb) and their low toxicity. To study their rate of formation and stability inside red cells, pyridoxal-Hb and PLP-Hb were measured in lysates from treated normal and sickle erythrocytes using isocratic high pressure liquid chromatography on Bio-Rex 70. The validity of this assay was confirmed by isoelectric focussing, fluorescence scans of reduced globin, and treatment of cells with pyridoxal 14C. Optimal conditions were described for treatment of whole blood with pyridoxal and washed erythrocytes with PLP. Although there was competition between 2,3-DPG and PLP, but not pyridoxal, for binding to Hb, depletion of 2,3-DPG prior to treatment was unnecessary. No special requirements were noted for the anticoagulants or buffers used. Sickle erythrocytes formed PLP-Hb more rapidly than normal erythrocytes, but pyridoxal-Hb appeared at the same rate in both types of erythrocytes. During incubation of treated erythrocytes in untreated plasma, the stability of pyridoxal-Hb varied inversely with the hematocrit, but PLP-Hb was stable at all hematocrits tested. The absence of hemolysis during a 4 day incubation of treated normal red cells implies that treatment with pyridoxal or PLP did not severely impair red cell metabolism.

UI MeSH Term Description Entries
D007525 Isoelectric Focusing Electrophoresis in which a pH gradient is established in a gel medium and proteins migrate until they reach the site (or focus) at which the pH is equal to their isoelectric point. Electrofocusing,Focusing, Isoelectric
D011730 Pyridoxal The 4-carboxyaldehyde form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid.
D011732 Pyridoxal Phosphate This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE). Pyridoxal 5-Phosphate,Pyridoxal-P,Phosphate, Pyridoxal,Pyridoxal 5 Phosphate,Pyridoxal P
D004913 Erythrocytes, Abnormal Oxygen-carrying RED BLOOD CELLS in mammalian blood that are abnormal in structure or function. Abnormal Erythrocytes,Abnormal Erythrocyte,Erythrocyte, Abnormal
D006441 Hemoglobin A Normal adult human hemoglobin. The globin moiety consists of two alpha and two beta chains.
D006451 Hemoglobin, Sickle An abnormal hemoglobin resulting from the substitution of valine for glutamic acid at position 6 of the beta chain of the globin moiety. The heterozygous state results in sickle cell trait, the homozygous in sickle cell anemia. Hemoglobin S,Deoxygenated Sickle Hemoglobin,Deoxyhemoglobin S,Hemoglobin SS,Hemoglobin, Deoxygenated Sickle,SS, Hemoglobin,Sickle Hemoglobin,Sickle Hemoglobin, Deoxygenated
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
January 1983, Biomedica biochimica acta,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
September 1974, Molecular biology,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
March 1988, The Journal of biological chemistry,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
January 1996, Biochimie,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
November 1982, Archives of biochemistry and biophysics,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
February 1982, The Journal of biological chemistry,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
January 1993, Molekuliarnaia biologiia,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
December 1974, The Journal of biological chemistry,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
January 1999, Biofizika,
J A Kark, and R Bongiovanni, and C U Hicks, and P G Tarassoff, and J S Hannah, and G Y Yoshida
August 1987, Journal of chromatography,
Copied contents to your clipboard!